ac
ACADIA Pharmaceuticals
ACAD
NASDAQ $21.83
How effective is ACADIA Pharmaceuticals's capital allocation strategy?
Positives: Acquiring ex‑North American rights to trofinetide in 2023 consolidated global economics; the company monetized the DAYBUE PRV for 150 million dollars; and it continues to invest behind two commercial franchises while advancing remlifanserin.
Negatives: Stock‑based compensation is meaningful and share count has increased, and the company incurred higher SG&A to scale commercial teams. Overall discipline is reasonable for a mid‑cap biotech, but dilution and spend creep merit monitoring.
Read the full report on ACADIA Pharmaceuticals and explore the other sections
Overview of ACADIA Pharmaceuticals
Does ACADIA Pharmaceuticals have a strong competitive moat?
Does ACADIA Pharmaceuticals have pricing power in its industry?
How predictable is ACADIA Pharmaceuticals's business?
Is ACADIA Pharmaceuticals financially strong?
How effective is ACADIA Pharmaceuticals's capital allocation strategy?
Does ACADIA Pharmaceuticals have high-quality management?
What is the fair value of ACADIA Pharmaceuticals stock?